Perioperative chemotherapy improves long-term survival of esophageal cancer patients: a systemic literatures review

食管癌围手术期治疗的疗效已得到肯定并被广泛接受,治疗方案包括放疗、化疗或放化疗联合治疗,给予的时间包括术前或术后.目前争议最多的治疗方案是围手术期化疗.本文针对围手术期单纯化疗,对已有相关研究和临床试验进行文献复习.文献回顾表明,食管癌围手术期化疗有效,但可能存在化疗优势人群,且以术前化疗效果为好.现有数据已足够证明围手术期化疗、尤其是术前新辅助化疗可改善EC的长期生存.The concept that peri-operative treatment could improve long-term survival of esophageal cancer patients has been universally accepted, including radiation alone, chemotherapy alone, and chemoradiation. The most controversial therapy is perioperative chemotherapy. Here we review the published literatures for reference. The result shows that perioperative chemotherapy is effective for esophageal cancer patients, especially for the so-called chemo-sensitive patients, and the preferred delivering time is before surgery. According to the current data, it is still unclear whether the efficacy of neoadjuvant chemotherapy is inferior to that of neoadjuvant chemoradiation.国家自然科学基金青年基金; 高等学校博士学科点专项科研基金; 北京市医院管理局临床医学发展专项经费资助; 北京市科技新星计划交叉合作课题(xxhz201405)教育部创新团队发展计划; 国家重点基础研究发展计划; 国家重点基础研究发展计划PubMed中文核心期刊要目总览(PKU)中国科技核心期刊(ISTIC)中国科学引文数据库(CSCD)4477-4801